Compare Home Depot Inc (HD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Home Depot Inc trades at $329.01 (market cap $332.08B), while Regeneron Pharmaceuticals Inc trades at $675.13 (market cap $70.47B). The key difference: Home Depot Inc is far larger — about 4.7× Regeneron Pharmaceuticals Inc's market cap, and Home Depot Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| HD | REGN | |
|---|---|---|
Market Cap | $332.08B | $70.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $812.27 |
52-Week Low | $297.51 | $545.46 |
Enterprise Value | $393.64B | $64.42B |
Dividend Yield | 2.8% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $331.77, down 2.1% today, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with a 128.38% ROE and 8.41% net margin, but faces weakening profit margins and high valuation multiples. Recent news highlights institutional trading activity and concerns over housing market headwinds.
The outlook remains cautious due to technical weakness and margin pressure, though analyst consensus is bullish with a $370.59 price target. Key risks include rising mortgage rates impacting demand, while opportunities lie in Pro segment growth and dividend stability. The stock trades near support at $330, requiring monitoring of Q2 2026 earnings for direction.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
